Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The fresh capital will propel Cordance into its first-in-human clinical trial
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Subscribe To Our Newsletter & Stay Updated